Navigation Links
Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
Date:10/21/2009

BETHESDA, Md., Oct. 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its Senior Vice President and Chief Financial Officer, Barclay Phillips, will present at The 8th Annual BIO Investor Forum on October 29, 2009 in San Francisco. A simultaneous webcast of the event will be available on the company's website at www.micromet-inc.com.

    Forum:      The 8th Annual BIO Investor Forum

    Date:       Thursday, October 29, 2009

    Time:       9:30 am U.S. Pacific Time

    Place:      Palace Hotel
                San Francisco, California

    Webcast:    www.micromet-inc.com

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking s
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
2. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
3. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
4. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
5. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
6. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
7. Micromet Key Events for 2009
8. Micromet Expands Committed Equity Financing Facility to $75 Million
9. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
10. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
11. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA ), a ... it has been named to Deloitte,s 2010 Technology Fast ... DUSA as one of the Top 500 fastest growing ... in North America.  Rankings are based on percentage of ...
... Oct. 26 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Officer of Neurocrine Biosciences, will be presenting at the Oppenheimer ... The live presentation takes place on Tuesday, November 2, ... Time.  The presentation will be webcast and may be accessed ...
Cached Medicine Technology:DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America 2
(Date:7/10/2014)... Teens who are sensitive to light or noise after ... such as anxiety and depression, a new study says. ... issues teens experience after concussion may help in planning ... when to return to play and what accommodations are ... Koehl and Dong Han, of the University of Kentucky ...
(Date:7/10/2014)... Dennis Thompson HealthDay ... About six out of 10 adults make use of calorie ... order in restaurants, according to a new U.S. study. ... lead author, Seung Hee Lee-Kwan, an epidemiologist with the U.S. ... women surveyed said they used menu labeling to help choose ...
(Date:7/10/2014)... with a microchip-based device developed at the Massachusetts General ... MGH Cancer Center can be cultured to establish cell ... the July 11 issue of Science , an ... reflect a tumor,s genetic mutation over time and changing ... culture cells from the blood that represent those present ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... Huddersfield could help to improve the quality of some ... as butter, mayonnaise, yoghurt and fruit drinks and ... her work. , Katerina gained her MSc degree in ... she has embarked on research for a PhD. ... investigating the potential of carbohydrates extracted from the pods ...
Breaking Medicine News(10 mins):Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:World interest in research work on the benefits of the Okra plant 2
... flying off the handle the next time someone cuts ... Yale School of Medicine researchers that links changes brought ... arrhythmias and sudden cardiac arrests, which are blamed for ... Lampert, M.D., associate professor of medicine at Yale School ...
... Feb. 24 Though the American Medical Association and ... funding of CME and though some big pharma companies ... even eliminating funding for CME by third-party vendors), 75 ... associations and teaching hospitals is funded by the bio-pharma ...
... from a baseball or hockey puck at just the right time could ... prevention were investigated in the March/April issue of Sports Health: A Multidisciplinary ... ... non-penetrating hit to the chest from a baseball or hockey puck at ...
... with the least education have a higher incidence of lung ... history accounts for approximately half of this risk, according to ... Journal of the National Cancer Institute. , Previous ... a higher risk for developing lung cancer. Some studies have ...
... chest pain are sent to a cardiologist to go through ... show no evidence of coronary artery disease which is the ... common occurrence in men, and these women are sent home ... their physicians complaining of similar symptoms and are more likely ...
... -- Ancient groundwater being tapped by Jordan, one of the ... to contain twenty times the radiation considered safe for drinking ... researchers. , "The combined activities of 228 radium and ... in the groundwater we tested are up to 2000 percent ...
Cached Medicine News:Health News:Educating the Market: Creating Value Through Support of Continuing Medical Education 2Health News:Study Shows Simple Measures May Help Prevent Sudden Death Event in Young Athletes 2Health News:Smoking behavior partially explains socioeconomic inequities in lung cancer incidence 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Jordan's fossil water source has high radiation levels 2Health News:Jordan's fossil water source has high radiation levels 3
... SPECIFICATIONS Form: Granular, free-flowing powder EEO (-m r ): ... less than or equal to 35C Remelt Point (3%): ... greater than or equal to 300 gm/cm 2 ... than or equal to 0.10% DNase: Passes test RNase: ...
... sulfate (SO 4 ) ≤ 1000 mg/kg Cation traces: ... ≤ 5 mg/kg Cr ≤ 5 mg/kg Cu ≤ ... mg/kg Mg ≤ 50 mg/kg Mn ≤ 5 mg/kg ... ≤ 5 mg/kg Zn ≤ 5 mg/kg Special grade: ...
... ≤ 500 mg/kg sulfate (SO 4 ) ≤ 1000 ... 5 mg/kg Co ≤ 5 mg/kg Cr ≤ 10 ... K ≤ 5 mg/kg Mg ≤ 5 mg/kg Mn ... 5 mg/kg Pb ≤ 5 mg/kg Zn ≤ 5 ...
Inquire...
Medicine Products: